Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by BOIARDI, L.
Right arrow Articles by PORTIOLI, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by BOIARDI, L.
Right arrow Articles by PORTIOLI, I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1996 British Society for Rheumatology

research-article

CD8 LYMPHOCYTE SUBSETS IN ACTIVE POLYMYALGIA RHEUMATICA: COMPARISON WITH ELDERLY-ONSET AND ADULT RHEUMATOID ARTHRITIS AND INFLUENCE OF PREDNISONE THERAPY

L. BOIARDI, C. SALVARANI, P. MACCHIONI, M. CASADEI MALDINI*, R. MANCINI*, E. BELTRANDI* and I. PORTIOLI

2nd Divisione di Medicina Interna (Unità Reumatologica) Azienda Ospedaliera Arcispedale S. Maria Nuova, Reggio Emilia
*Laboratorio di Patologia Clinica Ospedale Malpighi, Bologna, Italy

Correspondence to: Correspondence to: C. Salvarani, 2nd Divisione di Medicina Interna, Arcispedale S. Maria Nuova, V. le Umberto 1 n 50, 42100 Reggio Emilia, Italy.

The aim of this study was to evaluate CD8 lymphocyte subsets in active polymyalgia rhcumatica (PMR), to determine whether low percentages of CD8+ cells could be used to differentiate PMR from elderly-onset (EORA) and adult rheumatoid arthritis (RA), and to investigate the effects of prednisone on CD8 lymphocyte subsets. A significant reduction of percentages and absolute numbers of CD8bright+ cells was observed in patients with active PMR. Both CD8bright+ , CD57– and CD8bright+, CD57+ subsets were significantly reduced. Reduced percentages of CD8+ cells were observed in 55% of patients with active PMR/giant cell arteritis (GCA), in 23% with EORA and in 44% with adult RA. Prednisone therapy in PMR patients, after only 1 week, increased the lymphocyte count and the absolute numbers of lymphocyte subsets significantly. However, the percentages of CD8bright+ cells remained persistently low for the 2 yr study period in 80% of the patients with low pre-treatment levels. Our results demonstrate that CD8 cell percentage is a poor epidemiological discriminator for PMR diagnosis. Notwithstanding the rise in absolute numbers of CD8 cell subsets induced by prednisone, the persistently low percentages of CD8+ cells in a group of PMR patients indicate an abnormality connected with the disease.

KEY WORDS: Polymyalgia rheumatica, Elderly-onset rheumatoid arthritis, Adult rheumatoid arthritis, CD8+ cell subsets, Prednisone


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
R Caporali, C Montecucco, O Epis, F Bobbio-Pallavicini, T Maio, and M A Cimmino
Presenting features of polymyalgia rheumatica (PMR) and rheumatoid arthritis with PMR-like onset: a prospective study
Ann Rheum Dis, November 1, 2001; 60(11): 1021 - 1024.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
T Ellingsen, P Elling, A Olson, H Elling, U Baandrup, K Matsushima, B Deleuran, and K Stengaard-Pedersen
Monocyte chemoattractant protein 1 (MCP-1) in temporal arteritis and polymyalgia rheumatica
Ann Rheum Dis, October 1, 2000; 59(10): 775 - 780.
[Abstract] [Full Text]

Home page
 Ann Rheum DisHome page
M. A CIMMINO
Genetic and environmental factors in polymyalgia rheumatica
Ann Rheum Dis, October 1, 1997; 56(10): 576 - 577.
[Full Text]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.